Patent ID: 7820159

Claim:
A method of inhibiting EGF receptor dependent signaling on the phosphorylation of carbonic anhydrase 9 (MN/CA IX) in a human subject with renal cell carcinoma, wherein said disease is characterized by abnormal MN/CA9 gene expression, comprising: (a) obtaining a sample of body fluid or preneoplastic/neoplastic tissue from said human; (b) detecting and quantifying the level of MN/CA9 gene expression product in said sample; and (c) if said MN/CA9 gene expression product level in said sample is increased as compared to normal control, administering to said human a therapeutically effective amount of a composition comprising an EGFR tyrosine kinase inhibitor wherein said tyrosine kinase inhibitor inhibits EGFR dependent phosphorylation of MN/CA IX.